LUCD Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of --. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Lucid Diagnostics, Inc. has a consensus price target of $3.75, signalling upside risk potential of 253.77%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 648.85%. Given that Atossa Therapeutics, Inc. has higher upside potential than Lucid Diagnostics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Lucid Diagnostics, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 0.950, suggesting its less volatile than the S&P 500 by 4.956%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are larger than Atossa Therapeutics, Inc. quarterly revenues of --. Lucid Diagnostics, Inc.'s net income of -$10.4M is lower than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 20.14x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Celldex Therapeutics, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of -7753.43%. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Lucid Diagnostics, Inc. has a consensus price target of $3.75, signalling upside risk potential of 253.77%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 79.54%. Given that Lucid Diagnostics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Lucid Diagnostics, Inc. is more attractive than Celldex Therapeutics, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are larger than Celldex Therapeutics, Inc. quarterly revenues of --. Lucid Diagnostics, Inc.'s net income of -$10.4M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 20.14x versus 755.79x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of 84.08%. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Lucid Diagnostics, Inc. has a consensus price target of $3.75, signalling upside risk potential of 253.77%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 411.63%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Lucid Diagnostics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Lucid Diagnostics, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.753, suggesting its less volatile than the S&P 500 by 175.254%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are larger than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Lucid Diagnostics, Inc.'s net income of -$10.4M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 20.14x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed, Inc. has a net margin of -858.55% compared to Lucid Diagnostics, Inc.'s net margin of -120220%. Lucid Diagnostics, Inc.'s return on equity of -665.25% beat PAVmed, Inc.'s return on equity of 8.75%.

Lucid Diagnostics, Inc. has a consensus price target of $3.75, signalling upside risk potential of 253.77%. On the other hand PAVmed, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 3352.61%. Given that PAVmed, Inc. has higher upside potential than Lucid Diagnostics, Inc., analysts believe PAVmed, Inc. is more attractive than Lucid Diagnostics, Inc..

Lucid Diagnostics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.503%.

Lucid Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lucid Diagnostics, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.

Lucid Diagnostics, Inc. quarterly revenues are $1.2M, which are larger than PAVmed, Inc. quarterly revenues of $5K. Lucid Diagnostics, Inc.'s net income of -$10.4M is lower than PAVmed, Inc.'s net income of -$6M. Notably, Lucid Diagnostics, Inc.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lucid Diagnostics, Inc. is 20.14x versus 283.81x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.